Executive Summary

Phlaxis aims to fundamentally change the landscape of food allergies. One in every 12 children in the US suffer from food allergies with a CAGR of 3%. This epidemic is a threat to not only patients' personal health but also society, with economic costs measuring $25 billion annually in the US alone. Food management is extremely burdensome for both patients and their families, lowering overall quality of life and even causing life-threatening anaphylaxis reactions. Unfortunately, there is no therapeutic treatment that can cure food allergies, with existing options aiming only to mitigate severity. Phlaxis aims to change the game with a novel approach – an inverse vaccine to treat and prevent food allergies. Our patented platform uses an engineered glyco-vector to target the specific food allergen(s) of concern. Once injected, the treatment "teaches" the immune system to suppress future adverse reactions to the allergen. Laboratory animal model studies show promising preliminary data for both allergy prevention and treatment. While the platform has great flexibility between allergens, we have decided to focus initially on the treatment of peanut allergies, which are especially prevalent and rarely resolve naturally. The business opportunity is significant: With a target population of 1.1 million, we expect to see revenue approximating $1.0 billion the first year after entering the market with FDA approval. With patent expiration around ten years after entry, our product could yield a total revenue of $13.7 billion. The FDA drug approval process is stringent, but we've gained significant advantage in the fact that our platform is already being tested in human clinical trials for non-allergy diseases (multiple sclerosis and celiac disease). It is highly likely that our platform will be proven safe enough to launch a human clinical trial in the food allergy space. We believe that once in the trial phase, Phlaxis will be attractive to larger pharmaceutical companies as a strategic development partner or an acquisition target.